What did @weightdoc actually say?
The doctor summarized a new Obesity Medicine Association review article as a pragmatic update to their earlier position: not an endorsement of compounded GLP-1s, but a harm-reduction framework. The core claim is that the OMA now says, in effect, "we don't recommend it, but if you're going to do it, do it like this." That framing is mostly accurate, though it flattens some important nuance in the original document.
The creator walked through several specific OMA recommendations: the importance of a bona fide patient-prescriber relationship, confirming the drug is on the FDA shortage list, avoiding prescriptions driven by profit or prior-authorization avoidance, and a call to action for stakeholders to improve legitimate access to anti-obesity medications. The transcript closely mirrors the actual OMA document language, which is a point in the creator's favor.
Does the science back this up?
The OMA's position is consistent with the broader regulatory and clinical evidence base. Compounded semaglutide is not FDA-approved, and the agency has repeatedly warned that compounded versions have not been demonstrated to be bioequivalent to brand-name Ozempic or Wegovy. That matters clinically.
A 2023 FDA analysis flagged a rise in adverse event reports tied to compounded semaglutide, including dosing errors linked to unit confusion between mcg and mg. Separately, the FDA removed semaglutide from its drug shortage list in early 2025, which has significant legal implications for ongoing compounding under 503A and 503B frameworks. The creator doesn't mention this development, and it's arguably the most important current context for this entire conversation. Studies confirming the efficacy of brand-name semaglutide, like the STEP trials (Wilding et al., 2021, NEJM), cannot be extrapolated to compounded versions without independent bioequivalence data, which does not currently exist in the public literature.
What did they get wrong (or right)?
The creator is right that the OMA article is not a reversal of the association's earlier position. They are also right that it provides a clinician checklist and summarizes concerns including social media misinformation. These are accurate representations of a real document.
Where the video falls short is in what it omits. The FDA's removal of semaglutide from the shortage list in early 2025 means the OMA's own stated conditions for acceptable compounded use, specifically "during times of anti-obesity medication shortages" as confirmed by FDA listing, are no longer met for semaglutide specifically. The creator's conclusion, "evidence-based care is not always the best thing for an individual patient," is a real clinical philosophy, but stated without qualification it can be read as a soft justification for bypassing safety standards. That framing deserves scrutiny. Individual patient-centered care does not override the lack of bioequivalence data for compounded formulations.
What should you actually know?
If you are a patient considering compounded semaglutide, the most important fact right now is that the FDA shortage status of semaglutide has changed. As of early 2025, the FDA declared the shortage resolved, which effectively removes the primary legal basis under which many 503A pharmacies were compounding it. The OMA's own framework, as described in this video, conditions acceptable use on FDA shortage list confirmation. That condition is no longer satisfied for most semaglutide formulations.
The 503A versus 503B distinction the creator mentions is real and matters. Section 503A pharmacies compound for individual patients with a valid prescription. Section 503B outsourcing facilities can produce larger batches but are subject to stricter FDA oversight. Neither pathway produces a product that has been tested for bioequivalence to Wegovy or Ozempic. If you are prescribed either brand-name product by a legitimate clinician through a regulated telehealth platform, you are getting a medication with a known efficacy and safety profile. That is not a minor distinction.
- Always confirm your prescriber has a bona fide clinical relationship with you, not just an online questionnaire.
- Ask directly whether the pharmacy is 503A or 503B and whether it has current USP 797 and 795 compliance.
- Check the FDA shortage database yourself at accessdata.fda.gov before assuming shortage-based compounding is legally permissible.
Is this video a net positive or net negative for patients?
Mostly positive, with a significant caveat. The creator accurately represents a nuanced professional document, avoids sensationalism, and flags important ethical guardrails like prohibitions on profit-driven prescribing. The checklist framing is useful for both patients and clinicians. But the omission of the FDA's 2025 shortage resolution is a real gap that changes the legal and ethical calculus for the very practice being discussed. A video with 59,700 views that doesn't mention that update leaves a lot of patients with an incomplete picture.